Pierre Fabre Medicament

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

6 drugs in development

Phase 31

Phase 23

Phase 11

Preclinical2

By Therapeutic Area

top 2

Oncology

571%

Infectious Disease

114%

R&D Momentum

40/100

Pipeline Velocity

0/100

Trial Completion Rate

86/100

Pipeline Concentration

55/100

Pipeline Freshness

58/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Infectious Disease but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 9, 2026

Completed

Prospective Non-Interventional Study on Structum® in Adult Patients With Osteoarthritis

Earlier

Sep 3, 2026TrialMulticenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Sep 3, 2026TrialPhase I/II First-In-Human Open-label Trial to Assess Safety and Efficacy of STX-241 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Resistant to EGFR Tyrosine Kinase Inhibitors (TKIs).

Sep 3, 2026TrialA Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.

Sep 3, 2026TrialFirst-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Aug 1, 2026TrialAn Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein Barr Virus Associated Diseases (EBVision)

Jul 17, 2026TrialPhase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer

Jul 3, 2026TrialAdvanced Breast Cancer Patients Treated With Oral Vinorelbine: a Prospective and Retrospective, Observational Study - VINOREAL

4 more events

Oct 22, 2024TrialFIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Sep 22, 2023FDAExxua — EXXUA

Sep 30, 2022TrialTreatment Patterns of Neratinib in HER2+ EBC in China

Aug 31, 2022TrialBioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

ExxuaSep 2, 2030

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

STX-241Preclinical

Solid Tumor, Adult

KIN-2787Phase 1

Unknown / Other

Lymphoproliferative Disease

TabelecleucelPhase 3

Regulatory

Regulatory Timeline

19942 events

FDADec 23

Navelbine — NAVELBINE

Application NDA020388 (NDA)

FDADec 23

Navelbine — NAVELBINE

Application NDA020388 (NDA)

20231 event

FDASep 22

Exxua — EXXUA

Application NDA021164 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)